The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
about
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinomaUpdate on aurora kinase inhibitors in gynecologic malignancies.Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.Update on Aurora Kinase Targeted Therapeutics in Oncology.A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsHistone H3 phosphorylation (Ser10, Ser28) and phosphoacetylation (K9S10) are differentially associated with gene expression in liver of rats treated in vivo with acute ethanolNovel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).Mitosis as an anti-cancer drug target.Histone modifying enzymes: novel disease biomarkers and assay development.Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.The Aurora kinase inhibitors in cancer research and therapy.Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance.Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma.Hepatocyte polyploidization and its association with pathophysiological processesAurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma.Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth.A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.EpCAM-targeted therapy for human hepatocellular carcinoma.3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors.Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology.A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor.
P2860
Q30988387-E3A0A9D2-CDB2-4C76-BD5C-0CC95360A18FQ33709521-0D38EE0C-8010-4216-9F1D-DEDDE14BE69BQ34250364-6AB9D572-A144-4E48-BCF8-92484B91309AQ34576017-C435D7A3-D270-43E3-B83E-70F55257D401Q34621867-E451F1A9-D68D-4B8D-962B-FA5AED2B0874Q34941504-331DF2A8-D289-47F8-AE1E-DBCAE5EBAE11Q35289072-E1F68091-07B4-457B-9772-4E5739131BF1Q35688536-4D16FE8D-4547-4177-BD93-6CC4A354CA60Q36016223-0648F13C-27F6-454A-9193-8F0D164C4A34Q36367628-DB66005E-3C80-4BF2-8922-AC8F5C4FFF9CQ37722656-55A51BE5-A52C-4789-A8CB-41E2D80FB033Q37847073-216BDD7A-C0E0-4540-BD06-B3ACDC43D2E3Q37876882-3E7F23BF-3191-4DC4-9725-23E683461107Q38115166-8B0DF1F4-249D-4B1A-9CB3-2E4D85F674A2Q38691865-D2BEA21A-CB9E-4B5A-8E8B-296BDB87D77CQ38753586-FF88AC37-EC72-4B2F-8D97-9919A41D4C8AQ38756932-EAC2C3FE-88D0-4354-9CB3-0FCD321F85E6Q38806090-76FC1CF2-0245-4FB6-94A1-D699187CA072Q38902059-BFD2A023-FA39-4567-A614-EFF26A763537Q39198408-A0018765-AF59-4790-8238-604A72024519Q39245130-0C3629EA-91C8-4777-9229-18669A0C2D55Q39280414-8672317F-B7D7-41A4-AA4E-1A9B7A317A90Q39314764-75FFDC89-396E-4421-94FA-A3C778378C83Q42562915-ABCB7A15-EAA5-4AFE-8182-D49BAE6B873BQ47917582-42193631-C77E-42CA-B196-E75E83972BB2Q48632642-6713C28D-F17C-4E70-8E0F-E2D48EB19918Q53253202-5ADA47B4-7E18-4C2E-92D3-037B3254FB34Q53664285-60CA0947-B7C9-4FAF-BBC3-549F5D57B977Q54395760-75377E8A-85EF-4F2D-AAD4-08F4C1CBAE09Q54657116-F73BF188-41CF-4C15-8850-26A55423622BQ55033899-B890F1C8-B8E8-46EB-9BB6-9C609C0A5D1BQ55312817-42F03983-1B91-4583-B95A-C631FB4714DC
P2860
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@en
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@nl
type
label
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@en
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@nl
prefLabel
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@en
The selective Aurora B kinase ...... for hepatocellular carcinoma.
@nl
P2093
P1476
The selective Aurora B kinase ...... t for hepatocellular carcinoma
@en
P2093
Arihiro Aihara
Ayano Murakata
Mahmut Yasen
Noriaki Nakamura
Norio Noguchi
Satoshi Matsumura
Shigeki Arii
Shinji Tanaka
Yusuke Mitsunori
P356
10.1016/J.JHEP.2009.10.013
P50
P577
2009-10-29T00:00:00Z